double-skinned crabsVietnamese crab exporter
Advertisement
Advertisement

Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.

BiomedicineChina Future Tech /

Biomedicine

Related Topics:
Companies
Policy
Science
Industry Trends
Geopolitics
Illustration: Henry Wong
New medical drugs

6 of the best: the billion-dollar biotechs putting China on the map

China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.

Biomedicine: Industry Trends

Hong Kong needs new funding model to attract global drug makers: AstraZeneca

videocam
China technology

Chinese biopharma’s global expansion

Science

Biomedicine | China’s CAR-T cell therapy cancer breakthrough shows progress

Having played a pivotal role in the ‘astonishing’ growth of personalised cancer treatment, China this year became the first country in the world to approve its use on solid tumours.

China’s cancer breakthrough on CAR-T cell therapy shows progress
Biomedicine: Companies

AstraZeneca, Merck, Novo deals inject fresh global momentum into Chinese biotech

Deals involving novel cancer therapies and weight-loss drugs reinforce the growing global appeal of Chinese biotech innovation.

Biomedicine: Industry Trends

How Chinese biotech is graduating from licensing deals to broader partnerships

InnoCare’s pact with Eli Lilly, potentially worth up to US$3.35 billion, highlights a shift towards bigger partnerships, analysts say.

Advertisement
Advertisement
Advertisement
China technology

Are clinical trials about to become a new front in the US-China biotech race?

China’s ability to conduct clinical trials quickly and cheaply has given it an edge in the biotech sector – and the US is growing concerned.

A sign for the Food And Drug Administration outside its headquarters in Maryland. Photo: Getty Images
A sign for the Food And Drug Administration outside its headquarters in Maryland. Photo: Getty Images
Hong Kong stock market

‘High tide’ of China biotech deals seen as US curb fears fade: analysts

Stocks jump on reports Washington will allow most licensing deals under ‘substantially softer stance’ than had been feared, analysts say.

videocam
IPO

China’s tech IPOs weigh Hong Kong vs the mainland. But how much does it matter?

Firms weigh benefits of international reach against higher domestic valuations, but the dual-track dynamic is just the start, and it all aligns with Beijing’s goals.

videocam
Biomedicine: Policy

Biomedicine powerhouse: China targets quarter of global first-in-class drugs

New five-year plan aims to turn the sector into a pillar industry by 2030, driven by breakthroughs in technologies across critical fields.

The plan sets 10 targets, including requiring large pharmaceutical enterprises to generate combined revenue of no less than 3.5 trillion yuan. Photo: Shutterstock
Biomedicine: Companies

GSK’s US$750 million cancer drug deal highlights China’s rise as biotech player

The acquisition is the latest in a string of major licensing deals involving Chinese biotechnology firms.

4
GSK has agreed a deal worth up to US$750 million to license a T-cell engager from a Chinese biotechnology firm. Photo: Reuters
GSK has agreed a deal worth up to US$750 million to license a T-cell engager from a Chinese biotechnology firm. Photo: Reuters
Greater Bay Area

Hong Kong targets biomedicine powerhouse status in debut 5-year plan

Tied to the national strategy, the city’s first five-year blueprint doubles down on Greater Bay Area medical tech and healthcare cooperation.

Technology

As China embraces AI, few US pharmaceutical execs bet on it for innovation

Survey finds drug companies planned to scale AI or had already done so, but few anticipated a ‘wholesale revolution’ from the tech.

videocam
China’s private sector

China needs monkeys: lab animal shortage could hinder biotech growth

As fundraising and out-licensing deals in China grow, so does demand for monkeys and other primates for testing.

The expansion of China’s biotechnology industry is driving up demand for primates. Photo: Shutterstock
IPO

More Chinese developers of brain-computer interfaces move towards IPOs

Arfysica and Neuracle aim for Star Market listings amid what a Morgan Stanley analyst calls the ‘early stage of a multi-year IPO upcycle’.

videocam
The firms join a broader trend of hi-tech firms flocking to the Shanghai Stock Exchange’s Nasdaq-style Star Market. Photo: Xinhua
The firms join a broader trend of hi-tech firms flocking to the Shanghai Stock Exchange’s Nasdaq-style Star Market. Photo: Xinhua
China technology

China approves string of ‘telepathy’ devices amid push to leapfrog Elon Musk

Chinese regulators have approved a group of brain-technology products this year, as local start-ups push to surpass Musk’s Neuralink.

Banking & finance

Why Asian investors are pouring capital into brain tech and surgical robots

Family offices and venture investors across Hong Kong and the wider region are reshaping portfolios to capture long-term biotech growth.

Advertisement
Advertisement
Advertisement
Artificial intelligence

Biomedicine | China thinks big on brain-computer interfaces

Launch of commercial BCI implantation, ahead of US, offers hope to millions with brain or spinal injuries as plans are made for the technology’s wider use.

China thinks big on brain-computer interfaces after world-first surgery
Hong Kong stock market

China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial

The biliary tract cancer trial is the latest breakthrough for Akeso’s ivonescimab, which has also shown promise in treating some lung cancers.

Hong Kong stock market

China rushes to develop Moderna-style cancer vaccines amid market frenzy

Chinese biotech firms are already working on more than 100 cancer vaccines. Now, many are seeing their shares surge amid Moderna’s breakthrough.

videocam
7
Medicine

Overseas licensing has helped fuel China’s biotech profits. Will it last?

Out-licensing deals have overtaken IPOs as the primary lifeline for cash-starved Chinese drug makers, analysts say.

videocam
Asset id: 2156561481 Cross-border out-licensing deals are proving profitable for Chinese drugmakers. Photo: Shutterstock Images
Biomedicine: Industry Trends

Patience needed before human gene therapy trials, Stanford expert says

Human testing could take up to five years to ramp up, but AI approaches will yield results in time, Karoly Nikolich says.

videocam
Karoly Nikolich, pictured at the Hong Kong Convention and Exhibition Centre on August 8. Photo: Edmond So
Karoly Nikolich, pictured at the Hong Kong Convention and Exhibition Centre on August 8. Photo: Edmond So
China technology

The next tech race? China launches push to leapfrog US in ‘brain chip’ devices

China is throwing the power of the state behind efforts to overtake Elon Musk in a vital frontier technology: brain-computer interfaces.

14
China technology

China races to develop brain-computer interfaces that can be inserted in minutes

The technology – which allows patients to control digital devices using their thoughts – can be implanted like a stent in just a few minutes.

China’s private sector

Global pharma giants turn to Chinese biotech to tap innovation, valuation growth

The foreign investments can help Chinese companies grow and compete on the global stage, according to Citic Securities.

Test tubes are arranged in front of an AstraZeneca logo in this illustration picture taken May 21, 2021. Photo: Reuters
Help preserve 120 years of quality journalism.
SUPPORT NOW